Degarelix

Generic Name: Degarelix

Brand Names: Firmagon, Degarelix Accord

Drug Type: Small Molecule

Chemical Formula: C_₈₂H_₁₀₃ClN_₁₈O_₁₆

CAS Number: 214766-78-6

Unique Ingredient Identifier: SX0XJI3A11

Background: Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH) which ultimately causes testosterone s...

Indication: Degaralix is used for the management of advanced prostate cancer.

Associated Conditions: Advanced Prostate Cancer

Associated Therapies: -

Clinical Trials

Intramuscular Injections of Degarelix Administered in 1-Month Dosing Regimens in Patients With Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: Degarelix

First Posted Date: 2011-12-14

Last Posted Date: 2013-12-12

Lead Sponsor: Ferring Pharmaceuticals

Target Recruit Count: 76

Registration Number: NCT01491971

Locations: 🇺🇸
South Orange County Urology Research, Laguna Hills, California, United States
🇨🇦
Bramalea Medical Centre, Brampton, Ontario, Canada
🇺🇸
South Florida Medical Research, Aventura, Florida, United States

and more 12 locations

Feasibility and Toxicity of Degarelix for Prostate Downsizing Prior to Permanent Seed Prostate Brachytherapy

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: Degarelix

First Posted Date: 2011-10-05

Last Posted Date: 2020-01-27

Lead Sponsor: British Columbia Cancer Agency

Target Recruit Count: 50

Registration Number: NCT01446991

Locations: 🇨🇦
Abbottsford Cancer Center, Abbottsford, British Columbia, Canada
🇨🇦
Fraser Valley Cancer Center, Surrey, British Columbia, Canada
🇨🇦
Vancouver Cancer Center, Vancouver, British Columbia, Canada

Ipilimumab + Androgen Depravation Therapy in Prostate Cancer

Phase 2

Terminated

Conditions: Prostate Cancer

Interventions: Drug: Ipilimumab
Drug: Leuprolide
Drug: Goserelin
Drug: Degarelix

First Posted Date: 2011-06-21

Last Posted Date: 2023-09-29

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 30

Registration Number: NCT01377389

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Study to Find Maintenance Dose for Periodic Administration of ASP3550

Phase 2

Completed

Conditions: Prostatic Neoplasms

Interventions: Drug: degarelix

First Posted Date: 2010-12-16

Last Posted Date: 2024-10-31

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 155

Registration Number: NCT01261572

A Degarelix Trial in Patients With Prostate Cancer

Phase 3

Terminated

Conditions: Prostate Cancer

Interventions: Drug: Goserelin acetate
Drug: Degarelix

First Posted Date: 2010-11-17

Last Posted Date: 2015-06-03

Lead Sponsor: Ferring Pharmaceuticals

Target Recruit Count: 288

Registration Number: NCT01242748

Locations: 🇺🇸
Urology Associates of Dover, PA, Dover, Delaware, United States
🇨🇿
Vseobecna fakultni nemocnice v Praze, Praha 2, Praha, Czech Republic
🇫🇮
Pohjois-Karjalan keskussairaala, Tampere, Finland

and more 59 locations

A Study of Degarelix in Taiwanese Patients With Prostate Cancer

Phase 3

Completed

Conditions: Prostate Cancer

Interventions: Drug: Degarelix

First Posted Date: 2010-10-14

Last Posted Date: 2014-01-08

Lead Sponsor: Ferring Pharmaceuticals

Target Recruit Count: 110

Registration Number: NCT01220869

Locations: 🇨🇳
Taichung Veterans General Hospital, Taichung, Taiwan
🇨🇳
Chi-Mei Foundation Hospital, Tainan, Taiwan
🇨🇳
Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan

and more 7 locations

Long-Term Safety and Tolerability of Degarelix One-Month Dosing Regimen in Korean Patients

Phase 3

Completed

Conditions: Prostate Cancer

Interventions: Drug: Degarelix

First Posted Date: 2010-10-06

Last Posted Date: 2013-05-22

Lead Sponsor: Ferring Pharmaceuticals

Target Recruit Count: 127

Registration Number: NCT01215513

Locations: 🇰🇷
Seoul National University Bundang Hospital, Seongnam, Gyeonggi, Korea, Republic of
🇰🇷
Kyoungbuk National University Hospital, Daegu, Korea, Republic of
🇰🇷
Yonsei University Health System Gangnam Sevrance, Seoul, Eonguro, Gangnam-gu, Korea, Republic of

and more 8 locations

A Long Term Safety Study of Degarelix in Patients With Prostate Cancer

Phase 3

Completed

Conditions: Prostate Cancer

Interventions: Drug: Degarelix

First Posted Date: 2009-08-27

Last Posted Date: 2013-01-03

Lead Sponsor: Ferring Pharmaceuticals

Target Recruit Count: 77

Registration Number: NCT00967018

Locations: 🇪🇸
Hospital Universitari Vall d´Hebron, Barcelona, Spain
🇫🇷
Centre Paul Strauss, Strassbourg, France
🇧🇪
Institut Jules Bordet, Bruxelles, Belgium

and more 59 locations

A Trial of Degarelix in Patients With Prostate Cancer

Phase 3

Completed

Conditions: Prostate Cancer

Interventions: Drug: Goserelin acetate
Drug: Degarelix

First Posted Date: 2009-07-27

Last Posted Date: 2014-06-02

Lead Sponsor: Ferring Pharmaceuticals

Target Recruit Count: 859

Registration Number: NCT00946920

Locations: 🇺🇸
Arkansas Urology, Little Rock, Arkansas, United States
🇺🇸
Palm Beach Urology Associates, PA, Wellington, Florida, United States
🇧🇪
UZ Gent, Gent, Belgium

and more 121 locations

A Study of Degarelix in Patients With Prostate Cancer

Phase 3

Completed

Conditions: Prostate Cancer

Interventions: Drug: Degarelix
Drug: Leuprolide

First Posted Date: 2009-06-26

Last Posted Date: 2016-12-13

Lead Sponsor: Ferring Pharmaceuticals

Target Recruit Count: 409

Registration Number: NCT00928434

Locations: 🇺🇸
Southeastern Urology Center, PA, Tallahassee, Florida, United States
🇺🇸
Chesapeake Urology Associates, Baltimore, Maryland, United States
🇺🇸
Urology Associates Research, Englewood, Colorado, United States

and more 55 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy